Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Free Report) – Stock analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Artiva Biotherapeutics in a research note issued to investors on Wednesday, June 11th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.71) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.04) EPS, FY2026 earnings at ($4.09) EPS, FY2027 earnings at ($1.64) EPS, FY2028 earnings at ($1.03) EPS and FY2029 earnings at ($0.63) EPS.
Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.15).
View Our Latest Analysis on ARTV
Artiva Biotherapeutics Stock Performance
Artiva Biotherapeutics stock opened at $1.98 on Friday. The stock’s fifty day moving average price is $2.12 and its two-hundred day moving average price is $5.24. Artiva Biotherapeutics has a one year low of $1.78 and a one year high of $17.31.
Institutional Investors Weigh In On Artiva Biotherapeutics
Large investors have recently modified their holdings of the business. Wells Fargo & Company MN boosted its holdings in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after acquiring an additional 3,361 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock valued at $100,000 after acquiring an additional 7,151 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Artiva Biotherapeutics during the 1st quarter valued at $144,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Artiva Biotherapeutics by 26.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock valued at $165,000 after acquiring an additional 11,355 shares in the last quarter. Finally, Deutsche Bank AG acquired a new stake in shares of Artiva Biotherapeutics during the 4th quarter valued at $216,000.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Further Reading
- Five stocks we like better than Artiva Biotherapeutics
- NYSE Stocks Give Investors a Variety of Quality Options
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- Basic Materials Stocks Investing
- Alphabet Enters a Bull Market: Is It Time to Buy?
- How to Effectively Use the MarketBeat Ratings Screener
- Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.